Abstract
The influence two original derivatives of a therapeutically important peptide, bearing arachidonic acid residue with semax and proglyprol, upon platelet aggregation have been studied in vitro. It is established that both derivatives, in contrast to the parent peptide, possess moderate anti-aggregant properties and produce a dose-dependent decrease in the interplatelet interaction induced by ADP, epinephrine, and arachidonic acid within the concentration range of 0.018 - 1.8 mM. This activity was more pronounced for arachidonoylsemax in comparison with arachidonoylproglyprol.
MeSH terms
-
Adenosine Diphosphate / pharmacology
-
Adrenocorticotropic Hormone / analogs & derivatives*
-
Adrenocorticotropic Hormone / chemical synthesis
-
Adrenocorticotropic Hormone / pharmacology
-
Arachidonic Acid / chemistry*
-
Arachidonic Acid / pharmacology
-
Blood Platelets / cytology
-
Blood Platelets / drug effects
-
Cells, Cultured
-
Drug Design
-
Epinephrine / pharmacology
-
Humans
-
Neuroprotective Agents / chemical synthesis*
-
Neuroprotective Agents / pharmacology
-
Oligopeptides / chemical synthesis*
-
Oligopeptides / pharmacology
-
Peptide Fragments / chemical synthesis*
-
Peptide Fragments / pharmacology
-
Platelet Aggregation / drug effects*
-
Platelet Aggregation Inhibitors / chemical synthesis*
-
Platelet Aggregation Inhibitors / pharmacology
-
Proline / analogs & derivatives*
-
Proline / chemical synthesis
-
Proline / pharmacology
-
Structure-Activity Relationship
Substances
-
Neuroprotective Agents
-
Oligopeptides
-
Peptide Fragments
-
Platelet Aggregation Inhibitors
-
prolyl-glycyl-proline
-
Arachidonic Acid
-
Adenosine Diphosphate
-
ACTH (4-7), Pro-Gly-Pro-
-
Adrenocorticotropic Hormone
-
Proline
-
Epinephrine